Anbio Biotechnology NNNN
3.68 USD +0.10 (+2.65%)
At closeNov 4, 2026, 4:00 PM EST
3.68 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
3.55 Day range 3.79
3.09 52-week range 44.73
- YTD
- -87.76%
- 1 year
- -73.66%
Financial health
Altman Z-Score
1010.98 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-3 / 5 overall
- DCF 2
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E 188×
FY 2021 5y median 188× FY 2025
P/S 153×
FY 2021 5y median 124× FY 2025
P/B 43.8×
FY 2021 5y median 56.0× FY 2025
P/FCF -196×
FY 2021 5y median 138× FY 2025
EV/EBITDA 227×
FY 2021 5y median 226× FY 2025
EV/Sales 152×
FY 2021 5y median 122× FY 2025
FCF Yield -0.5%
FY 2021 5y median 0.5% FY 2025
Profitability
Gross Margin 87.2%
FY 2021 5y median 57.4% FY 2025
Operating Margin 66.7%
FY 2021 5y median 43.3% FY 2025
Net Margin 74.1%
FY 2021 5y median 42.5% FY 2025
ROE 21.2%
FY 2021 5y median 21.2% FY 2025
ROIC 19.1%
FY 2021 5y median 19.1% FY 2025
ROA 21.2%
FY 2021 5y median 21.2% FY 2025
Growth (YoY)
Revenue 5.6%
FY 2021 FY 2025
Operating Income 189.1%
FY 2021 FY 2025
EPS (diluted) 185.7%
FY 2021 FY 2025
Free Cash Flow -423.9%
FY 2021 FY 2025
Financial Health
Current Ratio 344×
FY 2021 5y median 10.7× FY 2025
Quick Ratio 344×
FY 2021 5y median 10.7× FY 2025
Debt / Equity 0.0×
FY 2021 5y median 0.0× FY 2025
Net Debt / EBITDA -1.3×
FY 2021 5y median -1.6× FY 2025
Interest Coverage 0.0×
FY 2021 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31